Wanke LA - Search Results

1

Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.

Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM. Kosinski M, et al. Among authors: wanke la. Am J Manag Care. 2002 Mar;8(3):231-40. Am J Manag Care. 2002. PMID: 11915973 Free article. Clinical Trial.

2

Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.

Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Mathias SD, et al. Clin Ther. 2000 Jan;22(1):128-39. doi: 10.1016/s0149-2918(00)87984-9. Clin Ther. 2000. PMID: 10688396 Clinical Trial.

3

Mononeuritis secondary to rheumatoid arthritis responds to etanercept.

Richter C, Wanke L, Steinmetz J, Reinhold-Keller E, Gross WL. Richter C, et al. Rheumatology (Oxford). 2000 Dec;39(12):1436-7. doi: 10.1093/rheumatology/39.12.1436. Rheumatology (Oxford). 2000. PMID: 11136899 No abstract available.

4

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.

Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Yelin E, et al. Arthritis Rheum. 2003 Nov;48(11):3046-54. doi: 10.1002/art.11285. Arthritis Rheum. 2003. PMID: 14613265 Free article.

5

Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis.

Etemad L, Yu EB, Wanke LA. Etemad L, et al. Among authors: wanke la. Manag Care Interface. 2005 Apr;18(4):21-7. Manag Care Interface. 2005. PMID: 15889759

6

Direct and indirect costs of rheumatoid arthritis to an employer.

Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC. Birnbaum HG, et al. Among authors: wanke la. J Occup Environ Med. 2000 Jun;42(6):588-96. doi: 10.1097/00043764-200006000-00006. J Occup Environ Med. 2000. PMID: 10874651

7

Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.

Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Payne R, et al. Among authors: wanke la. J Clin Oncol. 1998 Apr;16(4):1588-93. doi: 10.1200/JCO.1998.16.4.1588. J Clin Oncol. 1998. PMID: 9552070 Clinical Trial.

8

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.

Touchette DR, Durgin TL, Wanke LA, Goodkin DE. Touchette DR, et al. Among authors: wanke la. Clin Ther. 2003 Feb;25(2):611-34. doi: 10.1016/s0149-2918(03)80100-5. Clin Ther. 2003. PMID: 12749517

9

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.

Yelin E, Wanke LA. Yelin E, et al. Among authors: wanke la. Arthritis Rheum. 1999 Jun;42(6):1209-18. doi: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M. Arthritis Rheum. 1999. PMID: 10366114 Free article.

10

Applied pharmacoeconomics for tomorrow's climate. A blueprint for the changing healthcare environment.

Wanke LA. Wanke LA. Adm Radiol. 1994 Nov;13(11):59-61. Adm Radiol. 1994. PMID: 10139212 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results